Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
News and Views

Pharmaceutical Technology


People
BASi Extends President's Contract and Names Two Directors
Bioanalytical Systems (West Lafayette, IN) extended the employment contract of its president and CEO, Richard M. Shepperd, through December 31, 2009. Shepperd has served as interim president and CEO since October 2006.

In addition, BASi's board of directors filled two vacancies by electing Shepperd and Larry S. Boulet to serve as directors. Boulet is president of Boulet Consulting and serves on the Indiana State University Foundation 's board of directors.

Cyanta Hires Key Staff Members
Cyanta Drug Development Services (St. Louis, MO) hired John H. Gilbert as its vice-president and general manager. Gilbert will supervise the company's drug and medical-device development services. He will oversee contract projects such as methods development and validation, extractables and leachables, characterization, and stability studies.

Cyanta also named Melissa Porazzo its corporate quality-assurance officer. Porazzo will implement quality systems to ensure all data and reports operate within good manufacturing practices and good laboratory practices.

PAREXEL Appoints Vice-President of Data Sciences
PAREXEL International (Waltham, MA), a leading global pharmaceutical and biopharmaceutical services organization, appointed Dr. Barbara Tardiff to the newly created position of vice-president of data sciences. Tardiff will lead the expansion of the company's electronic data capture services. Tardiff joins PAREXEL after six years at Merck & Co., where she was the executive director of research information services. Tardiff previously served as the vice-president of informatics, data management, and biostatistics at Regeneron Pharmaceuticals.

IPS Forms Technical Advisory Board
Integrated Project Services (IPS, Lafayette Hill, PA) established a Technical Advisory Board composed of individuals who possess specialized knowledge and technical expertise. The Technical Advisory Board will augment IPS's senior management team and subject-matter experts to provide technical guidance and strategic direction to the company and its clients. Board members include James Agalloco and Metin šelik, who also are members of Pharmaceutical Technology's Editorial Advisory Board.

IPS is an engineering, design and build, validation, and compliance company that helps pharmaceutical and biotechnology companies improve their operations.

Expansions
Azopharma Broadens Services Network
Azopharma (Miramar, FL) established relationships with iQ Synthesis (St. Louis, MO) and Cyanta Drug Development (Maryland Heights, MO). The latter companies joined Azopharma's services network. IQ Synthesis will provide synthetic-chemistry services from the discovery to clinical phases. Cyanta Drug Development will offer its analytical-chemistry services from development to quality-control testing.

Azopharma's network has capabilities ranging from preclinical to manufacturing services and offers custom solutions to the pharmaceutical industries of North America, Europe, and Asia.

AcuTemp Holds Open House at New Headquarters
AcuTemp Thermal Systems (Dayton, OH), a manufacturer of insulation and temperature-sensitive transport solutions, held an open house at its newly remodeled corporate offices and manufacturing facilities. The renovation upgraded the 90,000-ft2 complex and more than doubled the space of the company's previous location. The manufacturing facility houses work areas that produce "ThermoCor" high-performance insulation and a suite of thermal containers to transport temperature-sensitive vaccines and pharmaceuticals.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here